Apyx Medical (APYX) EBIAT (2016 - 2025)
Apyx Medical (APYX) has disclosed EBIAT for 15 consecutive years, with -$1.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 74.36% year-over-year to -$1.2 million, compared with a TTM value of -$11.1 million through Dec 2025, up 52.95%, and an annual FY2025 reading of -$11.1 million, up 52.86% over the prior year.
- EBIAT was -$1.2 million for Q4 2025 at Apyx Medical, up from -$2.0 million in the prior quarter.
- Across five years, EBIAT topped out at -$1.0 million in Q2 2023 and bottomed at -$9.5 million in Q4 2023.
- Average EBIAT over 5 years is -$4.6 million, with a median of -$4.7 million recorded in 2023.
- The sharpest move saw EBIAT surged 81.22% in 2023, then crashed 546.32% in 2024.
- Year by year, EBIAT stood at -$2.0 million in 2021, then plummeted by 206.0% to -$6.1 million in 2022, then crashed by 56.42% to -$9.5 million in 2023, then skyrocketed by 50.21% to -$4.7 million in 2024, then skyrocketed by 74.36% to -$1.2 million in 2025.
- Business Quant data shows EBIAT for APYX at -$1.2 million in Q4 2025, -$2.0 million in Q3 2025, and -$3.7 million in Q2 2025.